Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer

Open access
Mehta, Anita K., Cheney, Emily M., Hartl, Christina A., Pantelidou, Constantia, Oliwa, Madisson, Castrillon, Jessica A., Lin, Jia-Ren, Hurst, Katie E., de Oliveira Taveira, Mateus, Johnson, Nathan T., Oldham, William M., Kalocsay, Marian, Berberich, Matthew J., Boswell, Sarah A., Kothari, Aditi, Johnson, Shawn, Dillon, Deborah A., Lipschitz, Mikel, Rodig, Scott, Santagata, Sandro, Garber, Judy E., Tung, Nadine, Yélamos, José, Thaxton, Jessica E., Mittendorf, Elizabeth A., Sorger, Peter K., Shapiro, Geoffrey I., Guerriero, Jennifer L.·2020·Nature Cancer

Abstract

Despite objective responses to poly(ADP-ribose) polymerase (PARP) inhibition and improvements in progression-free survival (PFS) compared to standard chemotherapy in patients with BRCA-associated triple-negative breast cancer (TNBC), benefits are transitory. Using high-dimensional single-cell profiling of human TNBC, here we demonstrate that macrophages are the predominant infiltrating immune cell type in breast cancer susceptibility (BRCA)-associated TNBC. Through multi-omics profiling, we show that PARP inhibitors enhance both anti- and pro-tumor features of macrophages through glucose and lipid metabolic reprogramming, driven by the sterol regulatory element-binding protein 1 (SREBF1, SREBP1) pathway. Combining PARP inhibitor therapy with colony-stimulating factor 1 receptor (CSF1R)-blocking antibodies significantly enhanced innate and adaptive antitumor immunity and extended survival in mice with BRCA-deficient tumors in vivo, and this was mediated by CD8+ T cells. Collectively, our results uncover macrophage-mediated immune suppression as a liability of PARP inhibitor treatment and demonstrate that combined PARP inhibition and macrophage-targeting therapy induces a durable reprogramming of the tumor microenvironment (TME), thus constituting a promising therapeutic strategy for TNBC. Mehta et al. show that PARP inhibition induces CSF1R-dependent immune-suppressive macrophages, and that its blockade restores PARP inhibitor efficacy and stimulates CD8+ T cell-dependent antitumor immunity in triple-negative breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43018-020-00148-7

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Cited by

See all 275

Metadata

Authors
Mehta, A. K., Cheney, E. M., Hartl, C. A., Pantelidou, C., Oliwa, M., Castrillon, J. A., Lin, J.-R., Hurst, K. E., de Oliveira Taveira, M., Johnson, N. T., Oldham, W. M., Kalocsay, M., Berberich, M. J., Boswell, S. A., Kothari, A., Johnson, S., Dillon, D. A., Lipschitz, M., Rodig, S., Santagata, S., Garber, J. E., Tung, N., Yélamos, J., Thaxton, J. E., Mittendorf, E. A., Sorger, P. K., Shapiro, G. I., & Guerriero, J. L.
Venue
Nature Cancer
Published
2020-12-14
Volume
2
Issue
1
Pages
66-82
ISSN
2662-1347 (ISSN-L)
OpenAlex
W3112241528
Cited by
275
References
80
FWCI
9.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. https://app.cochat.ai/papers/10.1038/s43018-020-00148-7
The paper
Mehta, A. K., Cheney, E. M., Hartl, C. A., Pantelidou, C., Oliwa, M., Castrillon, J. A., Lin, J.-R., Hurst, K. E., de Oliveira Taveira, M., Johnson, N. T., Oldham, W. M., Kalocsay, M., Berberich, M. J., Boswell, S. A., Kothari, A., Johnson, S., Dillon, D. A., Lipschitz, M., Rodig, S., . . . Guerriero, J. L. (2020). Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nature Cancer. https://doi.org/10.1038/s43018-020-00148-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.